Login to Your Account

CTI Tumbles 47 Percent On Missed Endpoint For Xyotax

By Karen Pihl-Carey

Tuesday, March 8, 2005
Cell Therapeutics Inc. lost almost half of its value Monday, following news that Xyotax missed the primary endpoint in its Stellar 3 pivotal trial in non-small-cell lung cancer patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription